Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph E Woolery

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Therapeutic Drug Monitoring|January 18, 2012
Posaconazole serum level on day 2 predicts steady state posaconazole serum levelMyke R Green, Joseph E Woolery
Mycoses|May 28, 2011
Optimising absorption of posaconazoleMyke R Green, Joseph E Woolery
American Journal of Therapeutics|July 2, 2010
Syndrome of inappropriate antidiuretic hormone secretion caused by high-dose bolus interleukin-2 therapy for metastatic melanomaMyke R Green, Joseph E Woolery, Emad Elquza
Expert Opinion on Drug Discovery|May 11, 2011
Update on Aurora Kinase Targeted Therapeutics in OncologyMyke R Green, Joseph E Woolery, Daruka Mahadevan
Anti-Cancer Drugs|October 10, 2012
Management of toxicities associated with high-dose interleukin-2 and biochemotherapyJamie C Poust, Joseph E Woolery, Myke R Green
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Therapeutic Drug Monitoring|January 18, 2012
Posaconazole serum level on day 2 predicts steady state posaconazole serum levelMyke R Green, Joseph E Woolery
Mycoses|May 28, 2011
Optimising absorption of posaconazoleMyke R Green, Joseph E Woolery
American Journal of Therapeutics|July 2, 2010
Syndrome of inappropriate antidiuretic hormone secretion caused by high-dose bolus interleukin-2 therapy for metastatic melanomaMyke R Green, Joseph E Woolery, Emad Elquza
Expert Opinion on Drug Discovery|May 11, 2011
Update on Aurora Kinase Targeted Therapeutics in OncologyMyke R Green, Joseph E Woolery, Daruka Mahadevan
Anti-Cancer Drugs|October 10, 2012
Management of toxicities associated with high-dose interleukin-2 and biochemotherapyJamie C Poust, Joseph E Woolery, Myke R Green
Pageof 1